Long-term effects of an intensive care admission during childhood

ISRCTN ISRCTN13571840
DOI https://doi.org/10.1186/ISRCTN13571840
Secondary identifying numbers S69234
Submission date
24/10/2024
Registration date
07/11/2024
Last edited
07/11/2024
Recruitment status
Recruiting
Overall study status
Ongoing
Condition category
Other
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data
Record updated in last year

Plain English summary of protocol

Background and study aims
Critically ill children are admitted to a pediatric intensive care unit (PICU) where they receive support for vital organ functions. Without this support, their risk of death is significantly high. Fortunately, major advancements in pediatric intensive care have reduced death rates to very low levels. Consequently, research has shifted from finding strategies to decrease death rates to reducing illness, both during PICU stays and after returning to daily life. Many survivors face health issues and problems in physical, emotional, social, and cognitive functioning, collectively referred to as post-intensive care syndrome in children (PICS-p). Previous studies focused on childhood issues, while the longer-term impacts during puberty, adolescence, and young adulthood remain insufficiently explored. This study aims to investigate the effects of critical illness on development during these crucial phases, particularly regarding puberty and body composition.

Who can participate?
Former PICU patients who were critically ill and healthy matched controls

What does the study involve?
The study will involve a comprehensive assessment of the development of former critically ill children 12 years after their PICU admission, comparing their growth, body composition, cardiometabolic risk factors, physical activity, health status, and puberty development with healthy peers. Evaluations will include clinical tests and questionnaires assessing neurocognitive functioning, emotional/behavioral health, and quality of life. Additionally, biological samples such as blood, urine, buccal swabs, and hair will be collected to investigate potential underlying mechanisms, focusing on epigenetic and hormonal/metabolic disruptions.

What are the possible benefits and risks of participating?
Possible benefits include contributing to a better understanding of long-term outcomes for critically ill children, potentially leading to improved preventive measures and management strategies for long-term issues. Risks are minimal but may involve the discomfort associated with biological sample collection and participating in clinical assessments.

Where is the study run from?
University Hospital Leuven (UZ Leuven) (Belgium)

When is the study starting and how long is it expected to run for?
September 2023 to June 2029

Who is funding the study?
Flemish Government Methusalem Program (Belgium)

Who is the main contact?
Prof. Dr Greet Van den Berghe, greet.vandenberghe@kuleuven.be

Contact information

Prof Greet Van den Berghe
Public, Principal Investigator

Herestraat 49
Leuven
3000
Belgium

ORCiD logoORCID ID 0000-0002-5320-1362
Phone +32 (0)16 344021
Email greet.vandenberghe@kuleuven.be
Prof Ilse Vanhorebeek
Scientific

Herestraat 49
Leuven
3000
Belgium

ORCiD logoORCID ID 0000-0002-5261-5192
Phone +32 (0)16 33 05 32
Email ilse.vanhorebeek@kuleuven.be
Prof Jan Gunst
Scientific

Herestraat 49
Leuven
3000
Belgium

ORCiD logoORCID ID 0000-0003-2470-6393
Phone +32 (0)16 34 40 21
Email jan.gunst@uzleuven.be
Dr An Jacobs
Scientific

Herestraat 49
Leuven
3000
Belgium

ORCiD logoORCID ID 0000-0003-2556-4454
Phone +32 (0)16348161
Email an.jacobs@uzleuven.be

Study information

Study designLong-term follow-up of an interventional randomized controlled trial
Primary study designInterventional
Secondary study designLong-term follow-up of an interventional randomized controlled trial
Study setting(s)Hospital
Study typeOther, Quality of life
Participant information sheet Not available in web format, please use the contact details to request a participant information sheet
Scientific titlePost-Intensive Care Syndrome in children (PICS-p): long-term harm extending into puberty, adolescence and young adulthood
Study acronymPICS-pub
Study objectivesPaediatric critical illness evokes a form of Post-Intensive Care Syndrome in children (PICS-p) that extends well beyond childhood, characterised by abnormal development into puberty, adolescence and young adulthood, with vulnerability depending on a priori identifiable risk factors.
Ethics approval(s)

Approved 18/10/2024, Ethics Committee Research UZ/KU Leuven (Herestraat 49, Leuven, 3000, Belgium; +32 (0)16 34 86 00; ec@uzleuven.be), ref: S69234

Health condition(s) or problem(s) studiedPost-intensive care syndrome in children
InterventionThis is a long-term follow-up study of former critically ill children who had been included in the large, multicentre PEPaNIC randomised controlled trial on the impact of early versus late initiation of supplemental parenteral nutrition in the PICU (n = 1440) and of a cohort of age- and sex-matched healthy children as controls (n = 441).

The former PEPaNIC patients will have a standardised assessment of clinical and functional outcomes 12 years after PICU admission, in parallel with similar follow-up of the control cohort. The researchers will collect blood, urine, buccal mucosa and hair samples.
Intervention typeOther
Primary outcome measure1. Clinical assessment of growth (measured height and body weight, calculated BMI, total body fat mass and total body muscle mass as measured via dual-energy X-ray absorption [DEXA] scan) at 12-year follow-up
2. The developmental stage of puberty at 12-year follow-up, as based on interrogation of Tanner stages with the use of a sex-specific questionnaire
Secondary outcome measuresAll outcomes are measured at the 12-year follow-up:
1. Health status: diagnosis of a somatic illness, diagnosis of a psychiatric illness, and incidence of hospital admission for medical, surgical or psychiatric reasons during the past 12 years for participants in the control group or during the 12 years following admission to the PICU for PEPaNIC participants. Measured by a structured interview with the parents or caregivers, and/or the participants if competent and old enough.
2. Additional measures of physical growth: measurement of leg length and sitting height, and calculation of the proportion of leg length over total height and sitting height ratio at 12-year follow-up.
3. Additional measures of body composition:
3.1. Total bone mass and localised (arms, legs, and trunk) bone mass, fat mass and lean tissue mass measured via dual-energy X-ray absorption (DEXA) scan at 12-year follow-up
3.2. Surrogate markers of body composition (waist circumference as a measure of central adiposity/obesity, skinfold thickness as a measure of subcutaneous body fat at the triceps and subscapular level (allowing estimation of body fat with the use of the Slaughter equation), a combination of mid-upper arm circumference and triceps skinfold as a marker of muscle mass.
4. Additional measures of pubertal and further development:
With the use of sex-specific questionnaires on pubertal development also interrogates other aspects of puberty development and the time of reaching specific a priori defined stages:
4.1. Development of axillary hair
4.2. Acne
4.3. Menarche
4.4. Growth of facial hair
4.5. First ejaculation of semen
4.6. Voice break
5. During the interrogation of medical history related to the occurrence of somatic illness or hospital admission, health conditions or previous therapies will be documented, including those that may interfere with pubertal development.
6. Where possible, the researchers also aim to evaluate the next crucial developmental stage going in the direction of measures of reproductive health/fertility:
6.1. Female participants will be asked about the heaviness and regularity of their menstruation/menstrual cycle
6.2. For male participants, serum inhibin B levels will be quantified as marker of the level of spermatogenesis, providing a valuable alternative for sperm sample analysis.
7. Biological parents of the participants will be interrogated regarding timing of their pubertal development (“normal”, “delayed” or “precocious” for the father; age menarche for the mother).
8. Bone age as determined by hand X-ray at 12-year follow-up
9. Cardiometabolic risk factors: systolic and diastolic blood pressure, glycated haemoglobin (HbA1c), insulin, glucose, high-molecular-weight adiponectin, leptin, triglycerides, LDL- and HDL-cholesterol at 12-year follow-up
10. Physical activity: daily physical activity assessed with an activity-tracking device (Actigraph accelerometer), measured for 7 days following the 12-year follow-up appointment.
11. Neurocognitive functioning at 12-year follow-up:
11.1. General intelligence measured using the Wechsler Intelligence Scale for Children or Adults
11.2. Visuo-motor integration measured using the Beery-Buktenica Developmental Test of Visual-Motor Integration
11.3. Attention and executive functions measured using the computerised tasks of the Amsterdam Neuropsychological Tasks system
11.4. Immediate and delayed verbal-auditory and visual memory measured using Children/Wechsler Memory Scales
11.5. Executive functioning measured using the Behaviour Rating Inventory of Executive Function questionnaire, with use of different informant-specific versions (parents/caregivers or participant self-report)
12. Emotional and behavioural problems will be assessed with internationally recognised and validated questionnaires:
12.1. Child Behaviour Checklist (CBCL) or Adult Behaviour Checklist (ABCL) to be completed by the parents/caregivers
12.2. Youth (YSR) or Adult Self Report (ASR) to be completed by the participants if competent
13. Daily life impact:
13.1. Interrogation of the participants’ school participation, highest level of education and/or employment status, leisure-time spending, ability to participate in social roles and activities, relationships, and use of follow-up services (semi-structured interview combined with PROMIS ability to participate in social roles and activities questionnaire items).
13.2. Subjective evaluation of physical, emotional, and social functioning of the participants in daily life: health-related quality-of-life questionnaires. For participants up to 17 years, the PROMIS Short Forms will be used.
Overall study start date01/09/2023
Completion date01/06/2029

Eligibility

Participant type(s)Healthy volunteer, Patient
Age groupMixed
Lower age limit12 Years
Upper age limit30 Years
SexBoth
Target number of participants1881 study participants in total are screened for inclusion
Key inclusion criteria1. Participated in the PEPaNIC trial as a critically ill patient or having been recruited as a healthy child within the control group for a longitudinal follow-up in parallel with the PEPaNIC patients
2. Survival up to the 12-year follow-up time point
Key exclusion criteriaNo informed consent
Date of first enrolment04/11/2024
Date of final enrolment31/12/2027

Locations

Countries of recruitment

  • Belgium
  • Netherlands

Study participating centres

UZ Leuven
Herestraat 49
Leuven
3000
Belgium
Erasmus MC
Dr. Wolewaterplein 40
Rotterdam
3015
Netherlands

Sponsor information

Universitair Ziekenhuis Leuven
Hospital/treatment centre

Herestraat 49
Leuven
3000
Belgium

Phone +32 (0)16 344021
Email onderzoek_ite@uzleuven.be
Website https://www.uzleuven.be/en
ROR logo "ROR" https://ror.org/0424bsv16

Funders

Funder type

Government

Vlaamse regering
Government organisation / National government
Alternative name(s)
Flanders, Flemish Government, Flandre, Flandern, Vlaanderen
Location
Belgium

Results and Publications

Intention to publish date01/06/2030
Individual participant data (IPD) Intention to shareYes
IPD sharing plan summaryStored in publicly available repository
Publication and dissemination planPlanned publication in a peer-reviewed journal
IPD sharing planThe datasets generated during and/or analysed during the current study will be stored in a publicly available repository (RDR; https://rdr.kuleuven.be/).

Editorial Notes

24/10/2024: Study's existence confirmed by Ethics Committee Research UZ/KU Leuven.